8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Revvity reports higher adjusted EPS and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
Revvity reported second-quarter 2026 revenue of $730 million and adjusted EPS of $1.41 for the period ended July 5, up from $1.18 a year earlier; pro forma revenue was $711 million, reflecting 4% growth. The company also agreed on July 31 to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue, for potential consideration of $140 million, with closing expected by the end of 2027 subject to approvals. Excluding the business, Revvity raised full-year 2026 guidance to $2.83 billion-$2.86 billion in revenue, 4%-5% pro forma organic growth, and $5.30-$5.40 in adjusted EPS.